TrialJAMA network open2021
Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma.
Chi-Leung Chiang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
33 papers cite it
this paperpooled itcites it